European Society of Breast Cancer Specialists EJC online - The official journal of EUSOMA Improving Breast Cancer Care in Europa
ABOUT EUSOMAGUIDELINES & PUBLICATIONSBREAST UNITSNEWSEVENTSBECOME A MEMBER
   Search            Home       Site map       Links       FAQ       Contact Us            

 

 


Other Guidelines

The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?


Diagnosis and management

 

1. Radiology 
2. Pathology/surgical
3. Radiotherapy
4. Endocrine therapy
5. Quality objective
6. Outcome measure

1. Radiology

Since most LCIS do not present as a mass nor contain microcalcification, mammography and ultrasound do not appear to have a role in prospectively diagnosing LCIS. LCIS may be associated with contrast enhancement in magnetic resonance imaging (MRI) and may therefore be visible, but this is usuallymasked by enhancement secondary to concomitant fibrocystic change, hence reliable diagnosis may not be possible even with MRI. However, PLCIS, which more often show microcalcification will be picked up because of similarities in presentation with DCIS [25] [26].

Radiology, however,may have a role in subsequent surveillance of patients following a diagnosis of LCIS, either to identify other preinvasive lesions such as DCIS or the invasive carcinoma that the patient would be at risk of. In particular, this may be important in high-risk women with a positive family history of breast cancer.

Although there are no data available on systematic randomised clinical trials regarding the efficacy of radiologic follow-up in women diagnosed with LCIS, and although we do not know whether it will improve outcome of women who develop invasive breast cancer, it seems reasonable to suggest at least the same degree of surveillance as is recommended in women at average risk. Accordingly, women who are diagnosed with LCIS should undergo annual two-view mammography of the affected and of the contralateral breast; in women with dense breasts (defined as mammograms rated as ACR II or higher) additional screening breast ultrasound should be considered. Whether or not women diagnosed with LCIS should undergo MRI for intensified surveillance as has been recently recommended in women with a genetically increased risk, is subject to current European clinical trials (e.g. MARIBS) [56].


Please use this address to send us any comments you want to make on the guidelines - we welcome your feedback: information@eusoma.org

 

     
 
Index
  Historical perspective
  Morphologic aspects
  Immunophenotype
  Risks associated with LCIS
  Molecular genetics
  Diagnosis and management
  Conflict of interest statement
  Acknowledgements
  References

 

 

| Webmaster | Privacy | Disclaimer | Credits |